<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240707141114&amp;fc=20230708114047&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240707141114&amp;fc=20230708114047&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Sun, 07 Jul 2024 18:11:16 +0000</lastbuilddate>
<pubDate>Sat, 06 Jul 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Early rhombic lip Protogenin&lt;sup>;+ve&lt;/sup>; stem cells in a human-specific neurovascular niche initiate and maintain group 3 medulloblastoma</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38971152/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240707141114&amp;v=2.18.0.post9+e462414
      <description>We identify a population of Protogenin-positive (PRTG^(+ve)) MYC^(high) NESTIN^(low) stem cells in the four-week-old human embryonic hindbrain that subsequently localizes to the ventricular zone of the rhombic lip (RL^(VZ)). Oncogenic transformation of early Prtg^(+ve) rhombic lip stem cells initiates group 3 medulloblastoma (Gr3-MB)-like tumors. PRTG^(+ve) stem cells grow adjacent to a human-specific interposed vascular plexus in the RL^(VZ), a phenotype that is recapitulated in Gr3-MB but not...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 26:S0092-8674(24)00651-2. doi: 10.1016/j.cell.2024.06.011. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">We identify a population of Protogenin-positive (PRTG<sup>+ve</sup>) MYC<sup>high</sup> NESTIN<sup>low</sup> stem cells in the four-week-old human embryonic hindbrain that subsequently localizes to the ventricular zone of the rhombic lip (RL<sup>VZ</sup>). Oncogenic transformation of early Prtg<sup>+ve</sup> rhombic lip stem cells initiates group 3 medulloblastoma (Gr3-MB)-like tumors. PRTG<sup>+ve</sup> stem cells grow adjacent to a human-specific interposed vascular plexus in the RL<sup>VZ</sup>, a phenotype that is recapitulated in Gr3-MB but not in other types of medulloblastoma. Co-culture of Gr3-MB with endothelial cells promotes tumor stem cell growth, with the endothelial cells adopting an immature phenotype. Targeting the PRTG<sup>high</sup> compartment of Gr3-MB in vivo using either the diphtheria toxin system or chimeric antigen receptor T cells constitutes effective therapy. Human Gr3-MBs likely arise from early embryonic RL<sup>VZ</sup> PRTG<sup>+ve</sup> stem cells inhabiting a specific perivascular niche. Targeting the PRTG<sup>high</sup> compartment and/or the perivascular niche represents an approach to treat children with Gr3-MB.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38971152/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240707141114&v=2.18.0.post9+e462414">38971152</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.06.011>10.1016/j.cell.2024.06.011</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38971152</guid>
<pubDate>Sat, 06 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Abhirami Visvanathan</dc:creator>
<dc:creator>Olivier Saulnier</dc:creator>
<dc:creator>Chuan Chen</dc:creator>
<dc:creator>Parthiv Haldipur</dc:creator>
<dc:creator>Wilda Orisme</dc:creator>
<dc:creator>Alberto Delaidelli</dc:creator>
<dc:creator>Seungmin Shin</dc:creator>
<dc:creator>Jake Millman</dc:creator>
<dc:creator>Andrew Bryant</dc:creator>
<dc:creator>Namal Abeysundara</dc:creator>
<dc:creator>Xujia Wu</dc:creator>
<dc:creator>Liam D Hendrikse</dc:creator>
<dc:creator>Vikas Patil</dc:creator>
<dc:creator>Zahedeh Bashardanesh</dc:creator>
<dc:creator>Joseph Golser</dc:creator>
<dc:creator>Bryn G Livingston</dc:creator>
<dc:creator>Takuma Nakashima</dc:creator>
<dc:creator>Yusuke Funakoshi</dc:creator>
<dc:creator>Winnie Ong</dc:creator>
<dc:creator>Alexandra Rasnitsyn</dc:creator>
<dc:creator>Kimberly A Aldinger</dc:creator>
<dc:creator>Cory M Richman</dc:creator>
<dc:creator>Randy Van Ommeren</dc:creator>
<dc:creator>John J Y Lee</dc:creator>
<dc:creator>Michelle Ly</dc:creator>
<dc:creator>Maria C Vladoiu</dc:creator>
<dc:creator>Kaitlin Kharas</dc:creator>
<dc:creator>Polina Balin</dc:creator>
<dc:creator>Anders W Erickson</dc:creator>
<dc:creator>Vernon Fong</dc:creator>
<dc:creator>Jiao Zhang</dc:creator>
<dc:creator>Raúl A Suárez</dc:creator>
<dc:creator>Hao Wang</dc:creator>
<dc:creator>Ning Huang</dc:creator>
<dc:creator>Jonelle G Pallota</dc:creator>
<dc:creator>Tajana Douglas</dc:creator>
<dc:creator>Joonas Haapasalo</dc:creator>
<dc:creator>Ferechte Razavi</dc:creator>
<dc:creator>Evelina Silvestri</dc:creator>
<dc:creator>Olga Sirbu</dc:creator>
<dc:creator>Samantha Worme</dc:creator>
<dc:creator>Michelle M Kameda-Smith</dc:creator>
<dc:creator>Xiaochong Wu</dc:creator>
<dc:creator>Craig Daniels</dc:creator>
<dc:creator>Antony K MichaelRaj</dc:creator>
<dc:creator>Aparna Badhuri</dc:creator>
<dc:creator>Daniel Schramek</dc:creator>
<dc:creator>Hiromichi Suzuki</dc:creator>
<dc:creator>Livia Garzia</dc:creator>
<dc:creator>Nabil Ahmed</dc:creator>
<dc:creator>Claudia L Kleinman</dc:creator>
<dc:creator>Lincoln D Stein</dc:creator>
<dc:creator>Peter Dirks</dc:creator>
<dc:creator>Christopher Dunham</dc:creator>
<dc:creator>Nada Jabado</dc:creator>
<dc:creator>Jeremy N Rich</dc:creator>
<dc:creator>Wei Li</dc:creator>
<dc:creator>Poul H Sorensen</dc:creator>
<dc:creator>Robert J Wechsler-Reya</dc:creator>
<dc:creator>William A Weiss</dc:creator>
<dc:creator>Kathleen J Millen</dc:creator>
<dc:creator>David W Ellison</dc:creator>
<dc:creator>Dimiter S Dimitrov</dc:creator>
<dc:creator>Michael D Taylor</dc:creator>
<dc:date>2024-07-06</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Early rhombic lip Protogenin&lt;sup>;+ve&lt;/sup>; stem cells in a human-specific neurovascular niche initiate and maintain group 3 medulloblastoma</dc:title>
<dc:identifier>pmid:38971152</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.06.011</dc:identifier>
</item>
<item>
<title>Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38971151/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240707141114&amp;v=2.18.0.post9+e462414
      <description>Homologous recombination deficiency (HRD) is prevalent in cancer, sensitizing tumor cells to poly (ADP-ribose) polymerase (PARP) inhibition. However, the impact of HRD and related therapies on the tumor microenvironment (TME) remains elusive. Our study generates single-cell gene expression and T cell receptor profiles, along with validatory multimodal datasets from >;100 high-grade serous ovarian cancer (HGSOC) samples, primarily from a phase II clinical trial (NCT04507841). Neoadjuvant...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jul 3:S0092-8674(24)00653-6. doi: 10.1016/j.cell.2024.06.013. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Homologous recombination deficiency (HRD) is prevalent in cancer, sensitizing tumor cells to poly (ADP-ribose) polymerase (PARP) inhibition. However, the impact of HRD and related therapies on the tumor microenvironment (TME) remains elusive. Our study generates single-cell gene expression and T cell receptor profiles, along with validatory multimodal datasets from >;100 high-grade serous ovarian cancer (HGSOC) samples, primarily from a phase II clinical trial (NCT04507841). Neoadjuvant monotherapy with the PARP inhibitor (PARPi) niraparib achieves impressive 62.5% and 73.6% response rates per RECIST v.1.1 and GCIG CA125, respectively. We identify effector regulatory T cells (eTregs) as key responders to HRD and neoadjuvant therapies, co-occurring with other tumor-reactive T cells, particularly terminally exhausted CD8<sup>+</sup> T cells (Tex). TME-wide interferon signaling correlates with cancer cells upregulating MHC class II and co-inhibitory ligands, potentially driving Treg and Tex fates. Depleting eTregs in HRD mouse models, with or without PARP inhibition, significantly suppresses tumor growth without observable toxicities, underscoring the potential of eTreg-focused therapeutics for HGSOC and other HRD-related tumors.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38971151/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240707141114&v=2.18.0.post9+e462414">38971151</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.06.013>10.1016/j.cell.2024.06.013</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38971151</guid>
<pubDate>Sat, 06 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Yikai Luo</dc:creator>
<dc:creator>Yu Xia</dc:creator>
<dc:creator>Dan Liu</dc:creator>
<dc:creator>Xiong Li</dc:creator>
<dc:creator>Huayi Li</dc:creator>
<dc:creator>Jiahao Liu</dc:creator>
<dc:creator>Dongchen Zhou</dc:creator>
<dc:creator>Yu Dong</dc:creator>
<dc:creator>Xin Li</dc:creator>
<dc:creator>Yiyu Qian</dc:creator>
<dc:creator>Cheng Xu</dc:creator>
<dc:creator>Kangjia Tao</dc:creator>
<dc:creator>Guannan Li</dc:creator>
<dc:creator>Wen Pan</dc:creator>
<dc:creator>Qing Zhong</dc:creator>
<dc:creator>Xingzhe Liu</dc:creator>
<dc:creator>Sen Xu</dc:creator>
<dc:creator>Zhi Wang</dc:creator>
<dc:creator>Ronghua Liu</dc:creator>
<dc:creator>Wei Zhang</dc:creator>
<dc:creator>Wanying Shan</dc:creator>
<dc:creator>Tian Fang</dc:creator>
<dc:creator>Siyuan Wang</dc:creator>
<dc:creator>Zikun Peng</dc:creator>
<dc:creator>Ping Jin</dc:creator>
<dc:creator>Ning Jin</dc:creator>
<dc:creator>Shennan Shi</dc:creator>
<dc:creator>Yuxin Chen</dc:creator>
<dc:creator>Mengjie Wang</dc:creator>
<dc:creator>Xiaofei Jiao</dc:creator>
<dc:creator>Mengshi Luo</dc:creator>
<dc:creator>Wenjian Gong</dc:creator>
<dc:creator>Ya Wang</dc:creator>
<dc:creator>Yue Yao</dc:creator>
<dc:creator>Yi Zhao</dc:creator>
<dc:creator>Xinlin Huang</dc:creator>
<dc:creator>Xuwo Ji</dc:creator>
<dc:creator>Zhaoren He</dc:creator>
<dc:creator>Guangnian Zhao</dc:creator>
<dc:creator>Rong Liu</dc:creator>
<dc:creator>Mingfu Wu</dc:creator>
<dc:creator>Gang Chen</dc:creator>
<dc:creator>Li Hong</dc:creator>
<dc:creator>COCPO Consortium</dc:creator>
<dc:creator>Ding Ma</dc:creator>
<dc:creator>Yong Fang</dc:creator>
<dc:creator>Han Liang</dc:creator>
<dc:creator>Qinglei Gao</dc:creator>
<dc:date>2024-07-06</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors</dc:title>
<dc:identifier>pmid:38971151</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.06.013</dc:identifier>
</item>
<item>
<title>Exercise Testing to Unmask Latent LVOT Obstruction in a Highly Symptomatic Patient With Hypertrophic Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38970597/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240707141114&amp;v=2.18.0.post9+e462414
      <description>Rest imaging in hypertrophic cardiomyopathy may underestimate or miss left ventricular outflow tract obstruction, leading to suboptimal management decisions that negatively affect symptomatic patients. The 2024 hypertrophic cardiomyopathy guidelines describe exercise stress testing as an important tool to determine overall exercise tolerance and latent, exercise-provoked left ventricular outflow tract obstruction.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 28:S0735-1097(24)07398-4. doi: 10.1016/j.jacc.2024.05.029. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Rest imaging in hypertrophic cardiomyopathy may underestimate or miss left ventricular outflow tract obstruction, leading to suboptimal management decisions that negatively affect symptomatic patients. The 2024 hypertrophic cardiomyopathy guidelines describe exercise stress testing as an important tool to determine overall exercise tolerance and latent, exercise-provoked left ventricular outflow tract obstruction.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38970597/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240707141114&v=2.18.0.post9+e462414">38970597</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.029>10.1016/j.jacc.2024.05.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38970597</guid>
<pubDate>Sat, 06 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Mustafa Husaini</dc:creator>
<dc:creator>Richard G Bach</dc:creator>
<dc:creator>Sharon Cresci</dc:creator>
<dc:date>2024-07-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Exercise Testing to Unmask Latent LVOT Obstruction in a Highly Symptomatic Patient With Hypertrophic Cardiomyopathy</dc:title>
<dc:identifier>pmid:38970597</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.029</dc:identifier>
</item>
<item>
<title>The LDL cumulative exposure hypothesis: evidence and practical applications</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38969749/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240707141114&amp;v=2.18.0.post9+e462414
      <description>The trapping of LDL and other apolipoprotein B-containing lipoproteins within the artery wall causes atherosclerosis. As more LDL becomes trapped within the artery wall over time, the atherosclerotic plaque burden gradually increases, raising the risk of an acute cardiovascular event. Therefore, the biological effect of LDL on the risk of atherosclerotic cardiovascular disease (ASCVD) depends on both the magnitude and duration of exposure. Maintaining low levels of LDL-cholesterol (LDL-C) over...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jul 5. doi: 10.1038/s41569-024-01039-5. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The trapping of LDL and other apolipoprotein B-containing lipoproteins within the artery wall causes atherosclerosis. As more LDL becomes trapped within the artery wall over time, the atherosclerotic plaque burden gradually increases, raising the risk of an acute cardiovascular event. Therefore, the biological effect of LDL on the risk of atherosclerotic cardiovascular disease (ASCVD) depends on both the magnitude and duration of exposure. Maintaining low levels of LDL-cholesterol (LDL-C) over time decreases the number of LDL particles trapped within the artery wall, slows the progression of atherosclerosis and, by delaying the age at which mature atherosclerotic plaques develop, substantially reduces the lifetime risk of ASCVD events. Summing LDL-C measurements over time to calculate cumulative exposure to LDL generates a unique biomarker that captures both the magnitude and duration of exposure, which facilitates the estimation of the absolute risk of having an acute cardiovascular event at any point in time. Titrating LDL-C lowering to keep cumulative exposure to LDL below the threshold at which acute cardiovascular events occur can effectively prevent ASCVD. In this Review, we provide the first comprehensive overview of how the LDL cumulative exposure hypothesis can guide the prevention of ASCVD. We also discuss the benefits of maintaining lower LDL-C levels over time and how this knowledge can be used to inform clinical practice guidelines as well as to design novel primary prevention trials and ASCVD prevention programmes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38969749/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240707141114&v=2.18.0.post9+e462414">38969749</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01039-5>10.1038/s41569-024-01039-5</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38969749</guid>
<pubDate>Fri, 05 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Brian A Ference</dc:creator>
<dc:creator>Eugene Braunwald</dc:creator>
<dc:creator>Alberico L Catapano</dc:creator>
<dc:date>2024-07-05</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>The LDL cumulative exposure hypothesis: evidence and practical applications</dc:title>
<dc:identifier>pmid:38969749</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01039-5</dc:identifier>
</item>
<item>
<title>Progestogen-driven B7-H4 contributes to onco-fetal immune tolerance</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38968937/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240707141114&amp;v=2.18.0.post9+e462414
      <description>Immune tolerance mechanisms are shared in cancer and pregnancy. Through cross-analyzing single-cell RNA-sequencing data from multiple human cancer types and the maternal-fetal interface, we found B7-H4 (VTCN1) is an onco-fetal immune tolerance checkpoint. We showed that genetic deficiency of B7-H4 resulted in immune activation and fetal resorption in allogeneic pregnancy models. Analogously, B7-H4 contributed to MPA/DMBA-induced breast cancer progression, accompanied by CD8^(+) T cell...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 28:S0092-8674(24)00652-4. doi: 10.1016/j.cell.2024.06.012. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Immune tolerance mechanisms are shared in cancer and pregnancy. Through cross-analyzing single-cell RNA-sequencing data from multiple human cancer types and the maternal-fetal interface, we found B7-H4 (VTCN1) is an onco-fetal immune tolerance checkpoint. We showed that genetic deficiency of B7-H4 resulted in immune activation and fetal resorption in allogeneic pregnancy models. Analogously, B7-H4 contributed to MPA/DMBA-induced breast cancer progression, accompanied by CD8<sup>+</sup> T cell exhaustion. Female hormone screening revealed that progesterone stimulated B7-H4 expression in placental and breast cancer cells. Mechanistically, progesterone receptor (PR) bound to a newly identified -58 kb enhancer, thereby mediating B7-H4 transcription via the PR-P300-BRD4 axis. PR antagonist or BRD4 degrader potentiated immunotherapy in a murine B7-H4<sup>+</sup> breast cancer model. Thus, our work unravels a mechanistic and biological connection of a female sex hormone (progesterone) to onco-fetal immune tolerance via B7-H4 and suggests that the PR-P300-BRD4 axis is targetable for treating B7-H4<sup>+</sup> cancer.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38968937/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240707141114&v=2.18.0.post9+e462414">38968937</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.06.012>10.1016/j.cell.2024.06.012</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38968937</guid>
<pubDate>Fri, 05 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Jiali Yu</dc:creator>
<dc:creator>Yijian Yan</dc:creator>
<dc:creator>Shasha Li</dc:creator>
<dc:creator>Ying Xu</dc:creator>
<dc:creator>Abhijit Parolia</dc:creator>
<dc:creator>Syed Rizvi</dc:creator>
<dc:creator>Weichao Wang</dc:creator>
<dc:creator>Yiwen Zhai</dc:creator>
<dc:creator>Rongxin Xiao</dc:creator>
<dc:creator>Xiong Li</dc:creator>
<dc:creator>Peng Liao</dc:creator>
<dc:creator>Jiajia Zhou</dc:creator>
<dc:creator>Karolina Okla</dc:creator>
<dc:creator>Heng Lin</dc:creator>
<dc:creator>Xun Lin</dc:creator>
<dc:creator>Sara Grove</dc:creator>
<dc:creator>Shuang Wei</dc:creator>
<dc:creator>Linda Vatan</dc:creator>
<dc:creator>Jiantao Hu</dc:creator>
<dc:creator>Justyna Szumilo</dc:creator>
<dc:creator>Jan Kotarski</dc:creator>
<dc:creator>Zachary T Freeman</dc:creator>
<dc:creator>Stephanie Skala</dc:creator>
<dc:creator>Max Wicha</dc:creator>
<dc:creator>Kathleen R Cho</dc:creator>
<dc:creator>Arul M Chinnaiyan</dc:creator>
<dc:creator>Samantha Schon</dc:creator>
<dc:creator>Fei Wen</dc:creator>
<dc:creator>Ilona Kryczek</dc:creator>
<dc:creator>Shaomeng Wang</dc:creator>
<dc:creator>Lieping Chen</dc:creator>
<dc:creator>Weiping Zou</dc:creator>
<dc:date>2024-07-05</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Progestogen-driven B7-H4 contributes to onco-fetal immune tolerance</dc:title>
<dc:identifier>pmid:38968937</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.06.012</dc:identifier>
</item>
<item>
<title>Excess Mortality and Loss of Life Expectancy After Myocardial Infarction: A Registry-Based Matched Cohort Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38966988/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240707141114&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: LOLE is higher in younger individuals, women, and those with reduced LVEF, but is attenuated when adjusting for comorbidities and risk factors. Advances in MI treatment during the past 30 years have almost halved LOLE, with no clear sign of leveling off to a plateau.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 5. doi: 10.1161/CIRCULATIONAHA.124.068739. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The effect of myocardial infarction (MI) on life expectancy is difficult to study because the prevalence of MI hinders direct comparison with the life expectancy of the general population. We sought to assess this in relation to age, sex, and left ventricular ejection fraction (LVEF) by comparing individuals with MI with matched comparators without previous MI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We included patients with a first MI between 1991 and 2022 from the nationwide SWEDEHEART registry (Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies), each matched with up to 5 comparators on age, sex, and region of residence. Flexible parametric survival models were used to estimate excess mortality risk and mean loss of life expectancy (LOLE) depending on index year, age, sex, and LVEF, and adjusted for differences in characteristics.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 335 748 cases were matched to 1 625 396 comparators. A higher LOLE was observed in younger individuals, women, and those with reduced LVEF (&lt;50%). In 2022, the unadjusted and adjusted mean LOLE spanned from 11.1 and 9.5 years in 50-year-old women with reduced LVEF to 5 and 3.7 months in 80-year-old men with preserved LVEF. Between 1992 and 2022, the adjusted mean LOLE decreased by 36% to 55%: from 4.4 to 2.0 years and from 3.3 to 1.9 years in 50-year-old women and men, respectively, and from 1.7 to 1.0 years and from 1.4 to 0.9 years in 80-year-old women and men, respectively.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: LOLE is higher in younger individuals, women, and those with reduced LVEF, but is attenuated when adjusting for comorbidities and risk factors. Advances in MI treatment during the past 30 years have almost halved LOLE, with no clear sign of leveling off to a plateau.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38966988/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240707141114&v=2.18.0.post9+e462414">38966988</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068739>10.1161/CIRCULATIONAHA.124.068739</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38966988</guid>
<pubDate>Fri, 05 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Christian Reitan</dc:creator>
<dc:creator>Pontus Andell</dc:creator>
<dc:creator>Joakim Alfredsson</dc:creator>
<dc:creator>David Erlinge</dc:creator>
<dc:creator>Robin Hofmann</dc:creator>
<dc:creator>Bertil Lindahl</dc:creator>
<dc:creator>Moa Simonsson</dc:creator>
<dc:creator>Paul W Dickman</dc:creator>
<dc:creator>Tomas Jernberg</dc:creator>
<dc:date>2024-07-05</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Excess Mortality and Loss of Life Expectancy After Myocardial Infarction: A Registry-Based Matched Cohort Study</dc:title>
<dc:identifier>pmid:38966988</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068739</dc:identifier>
</item>
<item>
<title>Intravascular ultrasound-guided drug-coated balloon angioplasty for femoropopliteal artery disease: a clinical trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38966936/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240707141114&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Intravascular ultrasound guidance significantly improved the outcomes of DCBs for FPA disease in terms of primary patency, freedom from clinically driven target lesion revascularization, and sustained clinical and haemodynamic improvement at 12 months. These benefits may be attributed to IVUS-guided optimization of the lesion before and after DCB treatment.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 5:ehae372. doi: 10.1093/eurheartj/ehae372. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Drug-coated balloons (DCBs) have demonstrated favourable outcomes following endovascular therapy for femoropopliteal artery (FPA) disease. However, uncertainty remains whether the use of intravascular ultrasound (IVUS) can improve the outcomes of DCBs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This prospective, multicentre, randomized trial, conducted at seven centres in South Korea, compared the outcomes of IVUS-guided vs. angiography-guided angioplasty for treating FPA disease with DCBs. Patients were assigned to receive IVUS-guided (n = 119) or angiography-guided (n = 118) angioplasty using DCBs. The primary endpoint was 12-month primary patency.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Between May 2016 and August 2022, 237 patients were enrolled and 204 (86.0%) completed the trial (median follow-up; 363 days). The IVUS guidance group showed significantly higher primary patency [83.8% vs. 70.1%; cumulative difference 19.6% (95% confidence interval 6.8 to 32.3); P = .01] and increased freedom from clinically driven target lesion revascularization [92.4% vs. 83.0%; difference 11.6% (95% confidence interval 3.1 to 20.1); P = .02], sustained clinical improvement (89.1% vs. 76.3%, P = .01), and haemodynamic improvement (82.4% vs. 66.9%, P = .01) at 12 months compared with the angiography guidance group. The IVUS group utilized larger balloon diameters and pressures for pre-dilation, more frequent post-dilation, and higher pressures for post-dilation, resulting in a greater post-procedural minimum lumen diameter (3.90 ± 0.59 vs. 3.71 ± 0.73 mm, P = .03).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Intravascular ultrasound guidance significantly improved the outcomes of DCBs for FPA disease in terms of primary patency, freedom from clinically driven target lesion revascularization, and sustained clinical and haemodynamic improvement at 12 months. These benefits may be attributed to IVUS-guided optimization of the lesion before and after DCB treatment.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38966936/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240707141114&v=2.18.0.post9+e462414">38966936</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae372>10.1093/eurheartj/ehae372</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38966936</guid>
<pubDate>Fri, 05 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Young-Guk Ko</dc:creator>
<dc:creator>Seung-Jun Lee</dc:creator>
<dc:creator>Chul-Min Ahn</dc:creator>
<dc:creator>Sang-Hyup Lee</dc:creator>
<dc:creator>Yong-Joon Lee</dc:creator>
<dc:creator>Byeong-Keuk Kim</dc:creator>
<dc:creator>Myeong-Ki Hong</dc:creator>
<dc:creator>Yangsoo Jang</dc:creator>
<dc:creator>Tae-Hoon Kim</dc:creator>
<dc:creator>Ha-Wook Park</dc:creator>
<dc:creator>Ji Yong Jang</dc:creator>
<dc:creator>Jae-Hwan Lee</dc:creator>
<dc:creator>Jae-Hyeong Park</dc:creator>
<dc:creator>Su Hong Kim</dc:creator>
<dc:creator>Eui Im</dc:creator>
<dc:creator>Sang-Ho Park</dc:creator>
<dc:creator>Donghoon Choi</dc:creator>
<dc:creator>IVUS-DCB investigators</dc:creator>
<dc:date>2024-07-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Intravascular ultrasound-guided drug-coated balloon angioplasty for femoropopliteal artery disease: a clinical trial</dc:title>
<dc:identifier>pmid:38966936</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae372</dc:identifier>
</item>
<item>
<title>TMPRSS2 and glycan receptors synergistically facilitate coronavirus entry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38964329/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240707141114&amp;v=2.18.0.post9+e462414
      <description>The entry of coronaviruses is initiated by spike recognition of host cellular receptors, involving proteinaceous and/or glycan receptors. Recently, TMPRSS2 was identified as the proteinaceous receptor for HCoV-HKU1 alongside sialoglycan as a glycan receptor. However, the underlying mechanisms for viral entry remain unknown. Here, we investigated the HCoV-HKU1C spike in the inactive, glycan-activated, and functionally anchored states, revealing that sialoglycan binding induces a conformational...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 21:S0092-8674(24)00656-1. doi: 10.1016/j.cell.2024.06.016. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The entry of coronaviruses is initiated by spike recognition of host cellular receptors, involving proteinaceous and/or glycan receptors. Recently, TMPRSS2 was identified as the proteinaceous receptor for HCoV-HKU1 alongside sialoglycan as a glycan receptor. However, the underlying mechanisms for viral entry remain unknown. Here, we investigated the HCoV-HKU1C spike in the inactive, glycan-activated, and functionally anchored states, revealing that sialoglycan binding induces a conformational change of the NTD and promotes the neighboring RBD of the spike to open for TMPRSS2 recognition, exhibiting a synergistic mechanism for the entry of HCoV-HKU1. The RBD of HCoV-HKU1 features an insertion subdomain that recognizes TMPRSS2 through three previously undiscovered interfaces. Furthermore, structural investigation of HCoV-HKU1A in combination with mutagenesis and binding assays confirms a conserved receptor recognition pattern adopted by HCoV-HKU1. These studies advance our understanding of the complex viral-host interactions during entry, laying the groundwork for developing new therapeutics against coronavirus-associated diseases.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38964329/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240707141114&v=2.18.0.post9+e462414">38964329</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.06.016>10.1016/j.cell.2024.06.016</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38964329</guid>
<pubDate>Thu, 04 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Haofeng Wang</dc:creator>
<dc:creator>Xiaoce Liu</dc:creator>
<dc:creator>Xiang Zhang</dc:creator>
<dc:creator>Zhuoqian Zhao</dc:creator>
<dc:creator>Yuchi Lu</dc:creator>
<dc:creator>Dingzhe Pu</dc:creator>
<dc:creator>Zeyang Zhang</dc:creator>
<dc:creator>Jie Chen</dc:creator>
<dc:creator>Yajie Wang</dc:creator>
<dc:creator>Mengfei Li</dc:creator>
<dc:creator>Xuxue Dong</dc:creator>
<dc:creator>Yinkai Duan</dc:creator>
<dc:creator>Yujia He</dc:creator>
<dc:creator>Qiyu Mao</dc:creator>
<dc:creator>Hangtian Guo</dc:creator>
<dc:creator>Haoran Sun</dc:creator>
<dc:creator>Yihan Zhou</dc:creator>
<dc:creator>Qi Yang</dc:creator>
<dc:creator>Yan Gao</dc:creator>
<dc:creator>Xiuna Yang</dc:creator>
<dc:creator>Hongzhi Cao</dc:creator>
<dc:creator>Luke Guddat</dc:creator>
<dc:creator>Lei Sun</dc:creator>
<dc:creator>Zihe Rao</dc:creator>
<dc:creator>Haitao Yang</dc:creator>
<dc:date>2024-07-04</dc:date>
<dc:source>Cell</dc:source>
<dc:title>TMPRSS2 and glycan receptors synergistically facilitate coronavirus entry</dc:title>
<dc:identifier>pmid:38964329</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.06.016</dc:identifier>
</item>
<item>
<title>Human coronavirus HKU1 recognition of the TMPRSS2 host receptor</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38964328/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240707141114&amp;v=2.18.0.post9+e462414
      <description>The human coronavirus HKU1 spike (S) glycoprotein engages host cell surface sialoglycans and transmembrane protease serine 2 (TMPRSS2) to initiate infection. The molecular basis of HKU1 binding to TMPRSS2 and determinants of host receptor tropism remain elusive. We designed an active human TMPRSS2 construct enabling high-yield recombinant production in human cells of this key therapeutic target. We determined a cryo-electron microscopy structure of the HKU1 RBD bound to human TMPRSS2, providing...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 26:S0092-8674(24)00646-9. doi: 10.1016/j.cell.2024.06.006. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The human coronavirus HKU1 spike (S) glycoprotein engages host cell surface sialoglycans and transmembrane protease serine 2 (TMPRSS2) to initiate infection. The molecular basis of HKU1 binding to TMPRSS2 and determinants of host receptor tropism remain elusive. We designed an active human TMPRSS2 construct enabling high-yield recombinant production in human cells of this key therapeutic target. We determined a cryo-electron microscopy structure of the HKU1 RBD bound to human TMPRSS2, providing a blueprint of the interactions supporting viral entry and explaining the specificity for TMPRSS2 among orthologous proteases. We identified TMPRSS2 orthologs from five mammalian orders promoting HKU1 S-mediated entry into cells along with key residues governing host receptor usage. Our data show that the TMPRSS2 binding motif is a site of vulnerability to neutralizing antibodies and suggest that HKU1 uses S conformational masking and glycan shielding to balance immune evasion and receptor engagement.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38964328/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240707141114&v=2.18.0.post9+e462414">38964328</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.06.006>10.1016/j.cell.2024.06.006</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38964328</guid>
<pubDate>Thu, 04 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Matthew McCallum</dc:creator>
<dc:creator>Young-Jun Park</dc:creator>
<dc:creator>Cameron Stewart</dc:creator>
<dc:creator>Kaitlin R Sprouse</dc:creator>
<dc:creator>Amin Addetia</dc:creator>
<dc:creator>Jack Brown</dc:creator>
<dc:creator>M Alejandra Tortorici</dc:creator>
<dc:creator>Cecily Gibson</dc:creator>
<dc:creator>Emily Wong</dc:creator>
<dc:creator>Margareta Ieven</dc:creator>
<dc:creator>Amalio Telenti</dc:creator>
<dc:creator>David Veesler</dc:creator>
<dc:date>2024-07-04</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Human coronavirus HKU1 recognition of the TMPRSS2 host receptor</dc:title>
<dc:identifier>pmid:38964328</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.06.006</dc:identifier>
</item>
<item>
<title>The life-saving benefit of dexamethasone in severe COVID-19 is linked to a reversal of monocyte dysregulation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38964327/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240707141114&amp;v=2.18.0.post9+e462414
      <description>Dexamethasone is a life-saving treatment for severe COVID-19, yet its mechanism of action is unknown, and many patients deteriorate or die despite timely treatment initiation. Here, we identify dexamethasone treatment-induced cellular and molecular changes associated with improved survival in COVID-19 patients. We observed a reversal of transcriptional hallmark signatures in monocytes associated with severe COVID-19 and the induction of a monocyte substate characterized by the expression of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jul 1:S0092-8674(24)00654-8. doi: 10.1016/j.cell.2024.06.014. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Dexamethasone is a life-saving treatment for severe COVID-19, yet its mechanism of action is unknown, and many patients deteriorate or die despite timely treatment initiation. Here, we identify dexamethasone treatment-induced cellular and molecular changes associated with improved survival in COVID-19 patients. We observed a reversal of transcriptional hallmark signatures in monocytes associated with severe COVID-19 and the induction of a monocyte substate characterized by the expression of glucocorticoid-response genes. These molecular responses to dexamethasone were detected in circulating and pulmonary monocytes, and they were directly linked to survival. Monocyte single-cell RNA sequencing (scRNA-seq)-derived signatures were enriched in whole blood transcriptomes of patients with fatal outcome in two independent cohorts, highlighting the potential for identifying non-responders refractory to dexamethasone. Our findings link the effects of dexamethasone to specific immunomodulation and reversal of monocyte dysregulation, and they highlight the potential of single-cell omics for monitoring in vivo target engagement of immunomodulatory drugs and for patient stratification for precision medicine approaches.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38964327/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240707141114&v=2.18.0.post9+e462414">38964327</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.06.014>10.1016/j.cell.2024.06.014</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38964327</guid>
<pubDate>Thu, 04 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Rainer Knoll</dc:creator>
<dc:creator>Elisa T Helbig</dc:creator>
<dc:creator>Kilian Dahm</dc:creator>
<dc:creator>Olufemi Bolaji</dc:creator>
<dc:creator>Frederik Hamm</dc:creator>
<dc:creator>Oliver Dietrich</dc:creator>
<dc:creator>Martina van Uelft</dc:creator>
<dc:creator>Sophie Müller</dc:creator>
<dc:creator>Lorenzo Bonaguro</dc:creator>
<dc:creator>Jonas Schulte-Schrepping</dc:creator>
<dc:creator>Lev Petrov</dc:creator>
<dc:creator>Benjamin Krämer</dc:creator>
<dc:creator>Michael Kraut</dc:creator>
<dc:creator>Paula Stubbemann</dc:creator>
<dc:creator>Charlotte Thibeault</dc:creator>
<dc:creator>Sophia Brumhard</dc:creator>
<dc:creator>Heidi Theis</dc:creator>
<dc:creator>Gudrun Hack</dc:creator>
<dc:creator>Elena De Domenico</dc:creator>
<dc:creator>Jacob Nattermann</dc:creator>
<dc:creator>Matthias Becker</dc:creator>
<dc:creator>Marc D Beyer</dc:creator>
<dc:creator>David Hillus</dc:creator>
<dc:creator>Philipp Georg</dc:creator>
<dc:creator>Constantin Loers</dc:creator>
<dc:creator>Janina Tiedemann</dc:creator>
<dc:creator>Pinkus Tober-Lau</dc:creator>
<dc:creator>Lena Lippert</dc:creator>
<dc:creator>Belén Millet Pascual-Leone</dc:creator>
<dc:creator>Frank Tacke</dc:creator>
<dc:creator>Gernot Rohde</dc:creator>
<dc:creator>Norbert Suttorp</dc:creator>
<dc:creator>Martin Witzenrath</dc:creator>
<dc:creator>CAPNETZ Study Group</dc:creator>
<dc:creator>Pa-COVID-19 Study Group</dc:creator>
<dc:creator>Antoine-Emmanuel Saliba</dc:creator>
<dc:creator>Thomas Ulas</dc:creator>
<dc:creator>Julia K Polansky</dc:creator>
<dc:creator>Birgit Sawitzki</dc:creator>
<dc:creator>Leif E Sander</dc:creator>
<dc:creator>Joachim L Schultze</dc:creator>
<dc:creator>Anna C Aschenbrenner</dc:creator>
<dc:creator>Florian Kurth</dc:creator>
<dc:date>2024-07-04</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The life-saving benefit of dexamethasone in severe COVID-19 is linked to a reversal of monocyte dysregulation</dc:title>
<dc:identifier>pmid:38964327</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.06.014</dc:identifier>
</item>
<item>
<title>Structural basis of TMPRSS2 zymogen activation and recognition by the HKU1 seasonal coronavirus</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38964326/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240707141114&amp;v=2.18.0.post9+e462414
      <description>The human seasonal coronavirus HKU1-CoV, which causes common colds worldwide, relies on the sequential binding to surface glycans and transmembrane serine protease 2 (TMPRSS2) for entry into target cells. TMPRSS2 is synthesized as a zymogen that undergoes autolytic activation to process its substrates. Several respiratory viruses, in particular coronaviruses, use TMPRSS2 for proteolytic priming of their surface spike protein to drive membrane fusion upon receptor binding. We describe the crystal...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 21:S0092-8674(24)00647-0. doi: 10.1016/j.cell.2024.06.007. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The human seasonal coronavirus HKU1-CoV, which causes common colds worldwide, relies on the sequential binding to surface glycans and transmembrane serine protease 2 (TMPRSS2) for entry into target cells. TMPRSS2 is synthesized as a zymogen that undergoes autolytic activation to process its substrates. Several respiratory viruses, in particular coronaviruses, use TMPRSS2 for proteolytic priming of their surface spike protein to drive membrane fusion upon receptor binding. We describe the crystal structure of the HKU1-CoV receptor binding domain in complex with TMPRSS2, showing that it recognizes residues lining the catalytic groove. Combined mutagenesis of interface residues and comparison across species highlight positions 417 and 469 as determinants of HKU1-CoV host tropism. The structure of a receptor-blocking nanobody in complex with zymogen or activated TMPRSS2 further provides the structural basis of TMPRSS2 activating conformational change, which alters loops recognized by HKU1-CoV and dramatically increases binding affinity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38964326/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240707141114&v=2.18.0.post9+e462414">38964326</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.06.007>10.1016/j.cell.2024.06.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38964326</guid>
<pubDate>Thu, 04 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Ignacio Fernández</dc:creator>
<dc:creator>Nell Saunders</dc:creator>
<dc:creator>Stéphane Duquerroy</dc:creator>
<dc:creator>William H Bolland</dc:creator>
<dc:creator>Atousa Arbabian</dc:creator>
<dc:creator>Eduard Baquero</dc:creator>
<dc:creator>Catherine Blanc</dc:creator>
<dc:creator>Pierre Lafaye</dc:creator>
<dc:creator>Ahmed Haouz</dc:creator>
<dc:creator>Julian Buchrieser</dc:creator>
<dc:creator>Olivier Schwartz</dc:creator>
<dc:creator>Félix A Rey</dc:creator>
<dc:date>2024-07-04</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Structural basis of TMPRSS2 zymogen activation and recognition by the HKU1 seasonal coronavirus</dc:title>
<dc:identifier>pmid:38964326</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.06.007</dc:identifier>
</item>
<item>
<title>TRIM35: A Proposed Gateway to p53-Induced Heart Failure Pathogenesis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38963873/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240707141114&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 5;135(2):314-316. doi: 10.1161/CIRCRESAHA.124.324792. Epub 2024 Jul 4.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38963873/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240707141114&v=2.18.0.post9+e462414">38963873</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324792>10.1161/CIRCRESAHA.124.324792</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38963873</guid>
<pubDate>Thu, 04 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Chang Jie Mick Lee</dc:creator>
<dc:creator>Roger S-Y Foo</dc:creator>
<dc:date>2024-07-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>TRIM35: A Proposed Gateway to p53-Induced Heart Failure Pathogenesis</dc:title>
<dc:identifier>pmid:38963873</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324792</dc:identifier>
</item>
<item>
<title>Combined Lipid Disturbances: More Than the Sum of Their Parts?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38963872/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240707141114&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 5;135(2):277-279. doi: 10.1161/CIRCRESAHA.124.324793. Epub 2024 Jul 4.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38963872/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240707141114&v=2.18.0.post9+e462414">38963872</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324793>10.1161/CIRCRESAHA.124.324793</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38963872</guid>
<pubDate>Thu, 04 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Robert A Hegele</dc:creator>
<dc:date>2024-07-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Combined Lipid Disturbances: More Than the Sum of Their Parts?</dc:title>
<dc:identifier>pmid:38963872</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324793</dc:identifier>
</item>
<item>
<title>Breaking Point: How Intraplaque Hemorrhage Propels Plaque Rupture</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38963871/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240707141114&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 5;135(2):317-319. doi: 10.1161/CIRCRESAHA.124.324795. Epub 2024 Jul 4.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38963871/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240707141114&v=2.18.0.post9+e462414">38963871</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324795>10.1161/CIRCRESAHA.124.324795</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38963871</guid>
<pubDate>Thu, 04 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Laura Parma</dc:creator>
<dc:creator>Johan Duchene</dc:creator>
<dc:creator>Christian Weber</dc:creator>
<dc:date>2024-07-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Breaking Point: How Intraplaque Hemorrhage Propels Plaque Rupture</dc:title>
<dc:identifier>pmid:38963871</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324795</dc:identifier>
</item>
<item>
<title>Phosphodiesterase Inhibitors in Cerebrovascular Perfusion and Pulsatility</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38963870/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240707141114&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 5;135(2):332-334. doi: 10.1161/CIRCRESAHA.124.324954. Epub 2024 Jul 4.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38963870/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240707141114&v=2.18.0.post9+e462414">38963870</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324954>10.1161/CIRCRESAHA.124.324954</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38963870</guid>
<pubDate>Thu, 04 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Jesus D Melgarejo</dc:creator>
<dc:date>2024-07-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Phosphodiesterase Inhibitors in Cerebrovascular Perfusion and Pulsatility</dc:title>
<dc:identifier>pmid:38963870</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324954</dc:identifier>
</item>
<item>
<title>"Tip" the Scale of Cardiac Repair via Reducing Pathological Extracellular Vesicles</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38963869/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240707141114&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 5;135(2):298-300. doi: 10.1161/CIRCRESAHA.124.324955. Epub 2024 Jul 4.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38963869/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240707141114&v=2.18.0.post9+e462414">38963869</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324955>10.1161/CIRCRESAHA.124.324955</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38963869</guid>
<pubDate>Thu, 04 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Zhang Yue</dc:creator>
<dc:creator>Ke Cheng</dc:creator>
<dc:date>2024-07-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>"Tip" the Scale of Cardiac Repair via Reducing Pathological Extracellular Vesicles</dc:title>
<dc:identifier>pmid:38963869</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324955</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38963868/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240707141114&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 5;135(2):262-264. doi: 10.1161/RES.0000000000000681. Epub 2024 Jul 4.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38963868/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240707141114&v=2.18.0.post9+e462414">38963868</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000681>10.1161/RES.0000000000000681</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38963868</guid>
<pubDate>Thu, 04 Jul 2024 06:00:00 -0400</pubDate>
<dc:date>2024-07-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:38963868</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000681</dc:identifier>
</item>
<item>
<title>Clinical Characteristics and Mechanisms of Acute Myocarditis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38963866/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240707141114&amp;v=2.18.0.post9+e462414
      <description>URL: https://www.clinicaltrials.gov; Unique identifier: NCT05335928.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 5;135(2):397-411. doi: 10.1161/CIRCRESAHA.124.324674. Epub 2024 Jul 4.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">URL: https://www.clinicaltrials.gov; Unique identifier: NCT05335928.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38963866/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240707141114&v=2.18.0.post9+e462414">38963866</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324674>10.1161/CIRCRESAHA.124.324674</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38963866</guid>
<pubDate>Thu, 04 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Stephane Heymans</dc:creator>
<dc:creator>Sophie Van Linthout</dc:creator>
<dc:creator>Sarah Mignon Kraus</dc:creator>
<dc:creator>Leslie T Cooper</dc:creator>
<dc:creator>Ntobeko A B Ntusi</dc:creator>
<dc:date>2024-07-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Clinical Characteristics and Mechanisms of Acute Myocarditis</dc:title>
<dc:identifier>pmid:38963866</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324674</dc:identifier>
</item>
<item>
<title>Exploring the Function of Epicardial Cells Beyond the Surface</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38963865/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240707141114&amp;v=2.18.0.post9+e462414
      <description>The epicardium, previously viewed as a passive outer layer around the heart, is now recognized as an essential component in development, regeneration, and repair. In this review, we explore the cellular and molecular makeup of the epicardium, highlighting its roles in heart regeneration and repair in zebrafish and salamanders, as well as its activation in young and adult postnatal mammals. We also examine the latest technologies used to study the function of epicardial cells for therapeutic...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 5;135(2):353-371. doi: 10.1161/CIRCRESAHA.124.321567. Epub 2024 Jul 4.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The epicardium, previously viewed as a passive outer layer around the heart, is now recognized as an essential component in development, regeneration, and repair. In this review, we explore the cellular and molecular makeup of the epicardium, highlighting its roles in heart regeneration and repair in zebrafish and salamanders, as well as its activation in young and adult postnatal mammals. We also examine the latest technologies used to study the function of epicardial cells for therapeutic interventions. Analysis of highly regenerative animal models shows that the epicardium is essential in regulating cardiomyocyte proliferation, transient fibrosis, and neovascularization. However, despite the epicardium's unique cellular programs to resolve cardiac damage, it remains unclear how to replicate these processes in nonregenerative mammalian organisms. During myocardial infarction, epicardial cells secrete signaling factors that modulate fibrotic, vascular, and inflammatory remodeling, which differentially enhance or inhibit cardiac repair. Recent transcriptomic studies have validated the cellular and molecular heterogeneity of the epicardium across various species and developmental stages, shedding further light on its function under pathological conditions. These studies have also provided insights into the function of regulatory epicardial-derived signaling molecules in various diseases, which could lead to new therapies and advances in reparative cardiovascular medicine. Moreover, insights gained from investigating epicardial cell function have initiated the development of novel techniques, including using human pluripotent stem cells and cardiac organoids to model reparative processes within the cardiovascular system. This growing understanding of epicardial function holds the potential for developing innovative therapeutic strategies aimed at addressing developmental heart disorders, enhancing regenerative therapies, and mitigating cardiovascular disease progression.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38963865/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240707141114&v=2.18.0.post9+e462414">38963865</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11225799/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240707141114&v=2.18.0.post9+e462414">PMC11225799</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.321567>10.1161/CIRCRESAHA.124.321567</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38963865</guid>
<pubDate>Thu, 04 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>David Wong</dc:creator>
<dc:creator>Julie Martinez</dc:creator>
<dc:creator>Pearl Quijada</dc:creator>
<dc:date>2024-07-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Exploring the Function of Epicardial Cells Beyond the Surface</dc:title>
<dc:identifier>pmid:38963865</dc:identifier>
<dc:identifier>pmc:PMC11225799</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.321567</dc:identifier>
</item>
<item>
<title>Mitochondrial Structure and Function in Human Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38963864/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240707141114&amp;v=2.18.0.post9+e462414
      <description>Despite clinical and scientific advancements, heart failure is the major cause of morbidity and mortality worldwide. Both mitochondrial dysfunction and inflammation contribute to the development and progression of heart failure. Although inflammation is crucial to reparative healing following acute cardiomyocyte injury, chronic inflammation damages the heart, impairs function, and decreases cardiac output. Mitochondria, which comprise one third of cardiomyocyte volume, may prove a potential...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 5;135(2):372-396. doi: 10.1161/CIRCRESAHA.124.323800. Epub 2024 Jul 4.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Despite clinical and scientific advancements, heart failure is the major cause of morbidity and mortality worldwide. Both mitochondrial dysfunction and inflammation contribute to the development and progression of heart failure. Although inflammation is crucial to reparative healing following acute cardiomyocyte injury, chronic inflammation damages the heart, impairs function, and decreases cardiac output. Mitochondria, which comprise one third of cardiomyocyte volume, may prove a potential therapeutic target for heart failure. Known primarily for energy production, mitochondria are also involved in other processes including calcium homeostasis and the regulation of cellular apoptosis. Mitochondrial function is closely related to morphology, which alters through mitochondrial dynamics, thus ensuring that the energy needs of the cell are met. However, in heart failure, changes in substrate use lead to mitochondrial dysfunction and impaired myocyte function. This review discusses mitochondrial and cristae dynamics, including the role of the mitochondria contact site and cristae organizing system complex in mitochondrial ultrastructure changes. Additionally, this review covers the role of mitochondria-endoplasmic reticulum contact sites, mitochondrial communication via nanotunnels, and altered metabolite production during heart failure. We highlight these often-neglected factors and promising clinical mitochondrial targets for heart failure.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38963864/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240707141114&v=2.18.0.post9+e462414">38963864</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11225798/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240707141114&v=2.18.0.post9+e462414">PMC11225798</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.323800>10.1161/CIRCRESAHA.124.323800</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38963864</guid>
<pubDate>Thu, 04 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Antentor Hinton</dc:creator>
<dc:creator>Steven M Claypool</dc:creator>
<dc:creator>Kit Neikirk</dc:creator>
<dc:creator>Nanami Senoo</dc:creator>
<dc:creator>Celestine N Wanjalla</dc:creator>
<dc:creator>Annet Kirabo</dc:creator>
<dc:creator>Clintoria R Williams</dc:creator>
<dc:date>2024-07-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Mitochondrial Structure and Function in Human Heart Failure</dc:title>
<dc:identifier>pmid:38963864</dc:identifier>
<dc:identifier>pmc:PMC11225798</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.323800</dc:identifier>
</item>
<item>
<title>Imaging of Existing and Newly Translated Proteins Elucidates Mechanisms of Sarcomere Turnover</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38962864/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240707141114&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our findings establish a unidirectional replacement model for cardiac sarcomeres subunit replacement and identify their turnover principles.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 4. doi: 10.1161/CIRCRESAHA.123.323819. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: How the sarcomeric complex is continuously turned over in long-living cardiomyocytes is unclear. According to the prevailing model of sarcomere maintenance, sarcomeres are maintained by cytoplasmic soluble protein pools with free recycling between pools and sarcomeres.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We imaged and quantified the turnover of expressed and endogenous sarcomeric proteins, including the giant protein titin, in cardiomyocytes in culture and in vivo, at the single cell and at the single sarcomere level using pulse-chase labeling of Halo-tagged proteins with covalent ligands.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We disprove the prevailing protein pool model and instead show an ordered mechanism in which only newly translated proteins enter the sarcomeric complex while older ones are removed and degraded. We also show that degradation is independent of protein age and that proteolytic extraction is a rate-limiting step in the turnover. We show that replacement of sarcomeric proteins occurs at a similar rate within cells and across the heart and is slower in adult cells.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our findings establish a unidirectional replacement model for cardiac sarcomeres subunit replacement and identify their turnover principles.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38962864/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240707141114&v=2.18.0.post9+e462414">38962864</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323819>10.1161/CIRCRESAHA.123.323819</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38962864</guid>
<pubDate>Thu, 04 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Guy Douvdevany</dc:creator>
<dc:creator>Itai Erlich</dc:creator>
<dc:creator>Lilac Haimovich-Caspi</dc:creator>
<dc:creator>Tomer Mashiah</dc:creator>
<dc:creator>Maksymilian Prondzynski</dc:creator>
<dc:creator>Maria Rosaria Pricolo</dc:creator>
<dc:creator>Jorge Alegre-Cebollada</dc:creator>
<dc:creator>Wolfgang A Linke</dc:creator>
<dc:creator>Lucie Carrier</dc:creator>
<dc:creator>Izhak Kehat</dc:creator>
<dc:date>2024-07-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Imaging of Existing and Newly Translated Proteins Elucidates Mechanisms of Sarcomere Turnover</dc:title>
<dc:identifier>pmid:38962864</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323819</dc:identifier>
</item>





























</channel>
</rss>